Pioneering RNA Therapeutics for Oncology: A Conversation with Geoff Nosrati of Nutcracker Therapeutics
Nutcracker Therapeutics micro logo

Pioneering RNA Therapeutics for Oncology: A Conversation with Geoff Nosrati of Nutcracker Therapeutics

Recent advances within the medical field have prompted the development of RNA therapeutics for many different applications. These therapeutics have the potential to greatly change the treatment landscape and create…

Continue Reading Pioneering RNA Therapeutics for Oncology: A Conversation with Geoff Nosrati of Nutcracker Therapeutics
First Patient Dosed: BBP-671 for Propionic Acidemia
Source: Pixabay

First Patient Dosed: BBP-671 for Propionic Acidemia

According to a news release from biopharmaceutical company BridgeBio Pharma, Inc., the first patient was dosed in a Phase 1 study. Researchers are evaluating the safety, tolerability, pharmacodynamics, and pharmacokinetics…

Continue Reading First Patient Dosed: BBP-671 for Propionic Acidemia
Myelodysplastic Syndromes: The FDA Grants Fast Track Designation for Eltanexor
source: pixabay.com

Myelodysplastic Syndromes: The FDA Grants Fast Track Designation for Eltanexor

  Karyopharm Therapeutics, a pharmaceutical company focusing on novel cancer therapies, has issued a statement via PR Newswire that the FDA has granted regulatory designations to eltanexor, Karyopharm’s Selective Inhibitor…

Continue Reading Myelodysplastic Syndromes: The FDA Grants Fast Track Designation for Eltanexor
Study of the Week: Study Reveals New Genetic Risk Factors for Non-Alcoholic Fatty Liver Disease
source: pixabay.com

Study of the Week: Study Reveals New Genetic Risk Factors for Non-Alcoholic Fatty Liver Disease

Welcome to Study of the Week from Patient Worthy. In this segment, we select a study we posted about from the previous week that we think is of particular interest…

Continue Reading Study of the Week: Study Reveals New Genetic Risk Factors for Non-Alcoholic Fatty Liver Disease
First Participant Dosed in IMG-004 Trial for Immunological Diseases
source: pixabay.com

First Participant Dosed in IMG-004 Trial for Immunological Diseases

  Near the start of August 2022, biotechnology company Inmagene Biopharmaceuticals ("Inmagene") and biopharmaceutical company HUTCHMED shared via news release that the first participant had been dosed in a Phase…

Continue Reading First Participant Dosed in IMG-004 Trial for Immunological Diseases

Study Data Shows Promise in LYS-SAF302 for Sanfilippo Syndrome Type A

Both the 3rd Annual Gene Therapy for Neurological Disorders meeting and the ADVANCE 2022 Sanfilippo Community Conference were held in July 2022. During both meetings, researchers presented new data from…

Continue Reading Study Data Shows Promise in LYS-SAF302 for Sanfilippo Syndrome Type A
Rare Classroom: Alkaptonuria
source: shutterstock

Rare Classroom: Alkaptonuria

Welcome to the Rare Classroom, a new series from Patient Worthy. Rare Classroom is designed for the curious reader who wants to get informed on some of the rarest, most…

Continue Reading Rare Classroom: Alkaptonuria